SCHEMBL5116418

SCHEMBL5116418

NC(=O)C(c1ccccc1)N(Cc1cccc(F)c1)S(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 6/20 0.50
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
DAGLA Q9Y4D2 1/20 0.44
PSEN1 P49768 3/20 0.43
PSEN2 P49810 3/20 0.43
APH1B Q8WW43 3/20 0.43
NCSTN Q92542 3/20 0.43
APH1A Q96BI3 3/20 0.43
PSENEN Q9NZ42 3/20 0.43
CXCR3 P49682 2/20 0.42
ADAMTS5 Q9UNA0 1/20 0.42
TRPM8 Q7Z2W7 1/20 0.42
PPARG P37231 1/20 0.41
PPARA Q07869 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5116415 1.00 TAS2R14 (0.50) TAS2R14MEN1KMT2AL3MBTL1DAGLA
SCHEMBL5127925 0.92 BMP1 (0.46) TAS2R14MEN1KMT2APSEN1PSEN2
SCHEMBL5127918 0.92 BMP1 (0.46) TAS2R14MEN1KMT2APSEN1PSEN2
SCHEMBL5127304 0.90 TAS2R14 (0.53) TAS2R14MEN1KMT2ADAGLAPSEN1
SCHEMBL5127299 0.90 TAS2R14 (0.53) TAS2R14MEN1KMT2ADAGLAPSEN1
SCHEMBL27659570 0.90 ADAMTS5 (0.50) TAS2R14MEN1KMT2AL3MBTL1PSEN1
SCHEMBL27659575 0.90 ADAMTS5 (0.50) TAS2R14MEN1KMT2AL3MBTL1PSEN1
SCHEMBL5117399 0.89 TAS2R14 (0.52) TAS2R14MEN1KMT2ADAGLAPSEN1
SCHEMBL5117393 0.89 TAS2R14 (0.52) TAS2R14MEN1KMT2ADAGLAPSEN1
SCHEMBL5127437 0.88 CXCR3 (0.50) TAS2R14MEN1KMT2ADAGLAPSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7163942-B2 Sulfonamide compounds for the treatment of neurodegenerative disorders PFIZER INC. (US) 2007-01-16 US claimed
US-20050222254-A1 Sulfonamide compounds for the treatment of neurodegenerative disorders PFIZER INC 2005-10-06 US claimed
US-7345095-B2 Sulfonamide compounds for the treatment of neurodegenerative disorders PFIZER INC (US) 2008-03-18 US disclosed
US-20070129349-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER INC 2007-06-07 US disclosed
EP-1747195-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Incorporated (US) 2007-01-31 EP disclosed
US-7163942-B2 Sulfonamide compounds for the treatment of neurodegenerative disorders PFIZER INC. (US) 2007-01-16 US disclosed
WO-2005095334-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS INC. (US) 2005-10-13 WO disclosed
US-20050222254-A1 Sulfonamide compounds for the treatment of neurodegenerative disorders PFIZER INC 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129349-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PSEN1, APP, PSEN2 TAS2R14 1345/4885MEN1 766/4885KMT2A 1535/4885
US-20050222254-A1 Sulfonamide compounds for the treatment of neurodegenerative disorders PSEN1, APP, PSEN2 TAS2R14 1257/4885MEN1 751/4885KMT2A 1547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.